摘要
目的观察华法令对于中、老年心房颤动病人抗凝治疗的有效性和安全性。方法对符合本研究标准的86例老年心颤动病人随机分为两组,华法令疗组(治疗组)和阿司匹林对照组(对照组),治疗组41例,给予华法林3mg/d开始,监测凝血酶原时间(PT)及国际标准化比值(INR)观察7～15d使INR达到2.0～3.0范围内,以后每月查1次INR。若病人需增加或减少药物或有出血倾向时随时再测INR。对照组45例,给予阿司匹林300mg/d,分2次服用。结果治疗组,平均9.7±2.1d,INR达2.0～3.0(平均2.5±0.12),其中INR在1.8～2.5(平均1.90±0.21)之间者占90.2%,治疗组有1例高血压心脏病病人出现脑梗死,而对照组有6例发生脑梗死,其余不良反应率两组差异无显著性。结论中、老年非瓣膜病心房颤动病人选择华法令2～3mg/d时,加强服药后监测及各药物间的相互作用,使INR保持在1.8～2.5之间是有效、安全的。
Objective To assess the effectiveness and security of warfarin in treatment of antico-agulation in old patients with chronic atrial fibrillation. Method The patients of chronic atrialfibrillation who were treatment group and control group PT and INR of the whole patients detected,thetreatment group were administed 3mg/d dose of warfarin.INR is in the range of 2.0～3.0 after 7～15days,and from then on ,INR were every month . When the patients were inclined to hemorrhagia symptom ,theirINR was detected immediately. The patients of control group were administered aspirin 300mg orally twicea day . Results INR of the treatment group attained to 2.0～3.0 after 7～15(9.7±2.1)days. It takes90.2%of the patients in the treatment group whose INR were attained to 1.8～2.5(1.90±0.21).Only onecase of the treatment group was found cerebral embolism, while 6 in the control group , there wassignificant difference. However, there was no any other significant difference in complications.Conclusion 2～3mg dose of oral warfarin in old chronic Af patients with INR in the range of 1.8～2.5 is effective, safe and convenient .
出处
《国际医药卫生导报》
2004年第14期12-14,共3页
International Medicine and Health Guidance News
关键词
心房颤动
非瓣膜病
中老年人
华法林
有效性
安全性
Middle-ageing patients Chronic atrial fibrillation Non-valvular disease WarfarinEffetiveness security
